Everis Medical in Kalamazoo Merges with Minnesota’s Hemostasis, Sixth Deal Since 2019

Everis Medical in Kalamazoo, a medical device company specializing in ear, nose, and throat, head and neck surgery, and adjacent surgical specialties, and Minnesota’s Hemostasis, an innovator in advanced sinus dressings and surgical hemostats, have merged.
1
Everis Medical, a medical device company specializing in ear, nose, and throat, head and neck surgery, has merged with Minnesota’s Hemostasis, an innovator in advanced sinus dressings and surgical hemostats.
Everis Medical, a medical device company specializing in ear, nose, and throat, head and neck surgery, has merged with Minnesota’s Hemostasis, an innovator in advanced sinus dressings and surgical hemostats. // Photo courtesy of Everis Medical

Everis Medical in Kalamazoo, a medical device company specializing in ear, nose, and throat, head and neck surgery, and adjacent surgical specialties, and Minnesota’s Hemostasis, an innovator in advanced sinus dressings and surgical hemostats, have merged.

The combined organization will operate as Everis Medical, with Hemostasis’ technologies and people becoming a core part of Everis, according to the companies. Terms of the merger were not disclosed.

The transaction is Everis’ sixth since 2019. It brings together two companies of comparable scale, and it gives the combined organization a cohesive portfolio for sinus and nasal surgery that includes repair and reconstruction, hemostasis, post-operative healing, and infection management.

“This is a defining moment for Everis,” says Kevin McLeod, founder and CEO, Everis Medical. “Hemostasis has built something rare — a proprietary technology platform that surgeons trust. Bringing our teams together creates a company with the scale, the portfolio, and the innovation engine to lead in ENT surgery.”

Michael Spearman, co-founder and chairman of Hemostasis, says, “From the start, we have been driven by a simple idea (that) continuous improvement and innovation leads to better outcomes for patients.

“Coming together with Everis is a true joining of two companies that share the same ambition. As part of Everis, our technologies will reach more surgeons and more patients, faster, and together we will continue advancing the technology in sinus dressings.”

The combined company will operate as Everis Medical, led by Kevin McLeod as CEO.

Hemostasis’ St. Paul, Minn. facility will continue to develop and manufacture the platform. Hemostasis technologies will continue to be sold under their existing brand names as part of the Everis portfolio. Customers of both companies are expected to experience a “seamless transition,” with uninterrupted access to technologies, service, and support.

“Everis and Hemostasis together form a stronger company than either could build alone,” says Don Pierce, partner at Shore Capital Partners and chairman of the Board of Everis. “This combination is exactly the kind of transformational step our partnership with Everis was designed to support, and we look forward to investing behind the combined team’s growth.”

For more information, visit everismedical.com and hemostasisllc.com.